• SIRT1/2 Inhibitor IV: Applied Research Workflows

  2026-08-31

  Build mechanism-focused assays around SIRT1/2 Inhibitor IV (cambinol) to connect deacetylase activity with lactate signaling, Ran modification, p53 acetylation, and tumor-cell responses. This practical guide separates evidence-backed observations from starting conditions for CNS injury, cancer, and metabolic pathway experiments.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-31

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible phenylaminothiazole-type kinase inhibitor for workflows involving KIT, PDGFRα, PDGFRβ, mast cells, and selected cancer models. It is not suitable for aqueous or ethanol-based protocols, broad-spectrum kinase screens, or clinical treatment decisions without independent evidence and validation.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-08-30

  A 2024 Theranostics study identifies the liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib-induced ferroptosis in hepatocellular carcinoma. Its mechanistic model links HNF4A-AS1 to METTL3-dependent m6A modification of DECR1 mRNA, polyunsaturated fatty acid retention, and drug sensitivity.

• CD36 Lipid Signaling Drives Immune Escape in AML

  2026-08-29

  Guo et al. identify a non-canonical CD36 lipid-sensing program in AML that links oxidized LDL and palmitate uptake to innate immune signaling, T-cell suppression, and resistance to decitabine. The study provides a mechanistic rationale for combining hypomethylating therapy with lipid-restriction strategies, while also defining important limits for translating the findings into other immunometabolic models.

• CD36 Lipid Signaling Drives Immune Escape in AML

  2026-08-28

  Guo et al. identify a non-canonical CD36-dependent lipid-signaling program in acute myeloid leukemia that links oxidized LDL and palmitate uptake to T cell suppression and resistance to decitabine. The study suggests that statin-mediated disruption of leukemic CD36 signaling may improve hypomethylating-agent efficacy, while also defining important metabolic and immunologic variables for future AML studies.

• Metoprolol Research Workflows for Beta1 Assays

  2026-08-28

  Build reproducible beta1-receptor, cardiovascular, inflammation, and exploratory tumor-biology assays with a defined small-molecule perturbation. This guide combines fresh-solution handling, concentration-response design, disease-state pharmacokinetic thinking, and troubleshooting strategies for Metoprolol BA2737.

• Temozolomide Workflows for Glioma DNA Damage

  2026-08-27

  Temozolomide provides a controlled way to impose DNA methylation stress in glioma and other cancer models. This guide connects practical dosing, ATRX-stratified combination assays, and troubleshooting strategies for DNA repair mechanism research and chemotherapy resistance studies.

• Central Control of Opioid Mechanical Hypersensitivity

  2026-08-27

  A 2024 Neuron study identifies a brain-to-spinal pathway linking MOR-expressing neurons in the lateral parabrachial nucleus to dynorphin and KOR-GABA circuits that regulate morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The findings distinguish mechanical opioid side effects from better-established thermal mechanisms and provide a circuit framework for receptor-specific pain mechanism research.

• Pterostilbene Preserves Dermal Fibroblast Mitochondria

  2026-08-26

  Zhou et al. show that pterostilbene reduces senescence in human dermal fibroblasts by improving mitochondrial quality and promoting mitophagy. The study combines cellular senescence, mitochondrial function, imaging, and UVB-exposed mouse models, providing a useful framework for evaluating dermal aging interventions.

• EZ Cap™ Firefly Luciferase mRNA as an LNP Probe

  2026-08-26

  EZ Cap™ Firefly Luciferase mRNA can do more than report gene expression: it can help separate payload quality from delivery-system performance. This article connects Cap 1 biology with lipid nanoparticle design and practical assay decisions.

• MEDUSA Links Death Rates to Drug Mechanisms

  2026-08-25

  Honeywell and colleagues introduce MEDUSA, a simulation-assisted framework that separates drug-treated cell growth from cell death in functional genomic screens. Applied to DNA damage, the method reveals that p53 loss redirects cells from apoptosis toward a respiration-dependent nonapoptotic death program, offering a more precise way to identify genetic determinants of drug lethality.

• Chemistry of Silybin: Structure, Separation, and Derivatives

  2026-08-25

  Křen and colleagues’ review reconstructs more than five decades of silybin chemistry, with particular emphasis on absolute stereochemical assignment, separation of silybin A and B, and derivative synthesis. Its practical importance is that it distinguishes the defined flavonolignan from the chemically heterogeneous silymarin mixture, improving the interpretation of analytical and biological experiments.

• Cy5 RNA labeling kit: Probe Workflow Guide

  2026-08-24

  Build fluorescent RNA probes by T7 transcription while tuning Cy5-UTP substitution to balance signal and transcript yield. This practical guide connects probe preparation with spatial hybridization, Northern analysis, and fluorescence tracking in RNA-delivery studies.

• Mdivi-1 Workflows for DRP1 and Mitochondrial Fission

  2026-08-24

  Mdivi-1 enables acute, cell-permeable suppression of DRP1-dependent mitochondrial fission for apoptosis assays, mitochondrial dynamics research, and ischemic-retina models. This practical guide connects dosing and imaging workflows with the emerging extracellular-matrix-to-mitochondria signaling framework.

• Indole-3-pyruvic acid: Experimental Workflows

  2026-08-23

  Indole-3-pyruvic acid connects plant auxin biosynthesis, fungal metabolite tracing, and mammalian AhR studies in one versatile experimental framework. This guide translates its pathway biology into practical assay design, control selection, and troubleshooting strategies.

7422 records 8/495 page Previous Next First page 上5页 678910 下5页 Last page